Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 35M | 0.9% |
| Net Income | -33M | 142.5% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 285M | 9.8% |
| Total Liabilities | 75M | 0.5% |
| Total Equity | 210M | 12.7% |
| Shares Outstanding | 86M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -28M | 20.3% |
EPS
Financial Highlights for Century Therapeutics in Q2 '25
Operating Expenses for this period were 35M, showing a -0.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -33M, showing a -142.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Century Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
